Article

Ventricular Unloading and Inflammation – The Role of Impella in Myocarditis

Permissions
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
Information image
Average (ratings)
No ratings
Your rating
Copyright Statement:

The copyright in this work belongs to Radcliffe Medical Media. Only articles clearly marked with the CC BY-NC logo are published with the Creative Commons by Attribution Licence. The CC BY-NC option was not available for Radcliffe journals before 1 January 2019. Articles marked ‘Open Access’ but not marked ‘CC BY-NC’ are made freely accessible at the time of publication but are subject to standard copyright law regarding reproduction and distribution. Permission is required for reuse of this content.

Dr Tschöpe is a Professor of Medicine and Cardiology and the Vice Director of the Department of Cardiology, Charité, CVK, Berlin, guiding the cardiomyopathy programme. His main research interests are the potential of cell therapies to cure heart failure and the role of the immune system in heart failure.

Acute fulminant myocarditis and giant cell myocarditis have a poor prognosis.1 At present, short-term mechanical circulatory support (MCS) for myocarditis patients with refractory cardiogenic shock (CS) has predominantly used extracorporeal membrane oxygenation (ECMO),2 despite the use of Impella CP® for all other CS situations. Several case reports of successful short-term use of the Impella in fulminant myocarditis and giant cell myocarditis have been published.3–7

Use of the Impella in a patient with myocarditis – NT-pro brain natriuretic peptide levels

Article image

Use of the Impella in a patient with myocarditis – left ventricle ejection fraction and strain

Article image

These reports have suggested that peripheral unloading with the Impella may not be merely providing circulatory support, but it also may be conferring additional anti-inflammatory effects that modify the disease state, thus allowing a bridge to recovery in patients with fulminant myocarditis. In order to explore this hypothesis further, Dr Tschöpe presented the known pathophysiological processes underlying myocarditis, including pro-inflammatory and fibrotic processes that lead to cardiac remodelling and failure during disease progression. In an overloaded myocardium such as is present during fulminant myocarditis, mechanical stress activates integrins (mechanoreceptors) in the heart, which are known to mediate pro-inflammatory and fibrotic processes. Furthermore, integrins are known to have direct detrimental effects on the contractile apparatus. These combined effects exacerbate myocarditis, and contribute to the observed poor patient outcomes. Therefore, the hypothesis is logically raised whether haemodynamically unloading the heart by means of MCS (thereby decreasing mechanical stress) is a sufficient means to overcoming these pathophysiological mechanisms.

 

Immune cell presence after unloading in a case of acute fulminant myocarditis

Article image

The hypothesis that mechanical unloading may improve reverse remodelling in fulminant myocarditis was tested in a 62-yearold patient recently admitted to the practice of Dr Tschöpe with severe myocarditis and pre-CS despite immunosuppressive therapy. An axillary Impella 5.0 was implanted, which remained in place for 40 days. After 2 days in bed, the patient was mobile. Steroid therapy and unloading gave a significant improvement in ejection fraction from 5 days after implantation. In addition, the patient’s NT-pro brain natriuretic peptide levels reduced over time (see Figure 1), and increases were seen in EF and global longitudinal strain during short-time loading (see Figure 2). After 4 weeks, an echocardiogram showed the first signs of recovery.

Serial left ventricular biopsies taken at various time points during treatment to assess biomarkers of inflammation. These data demonstrate that the inflammatory response was significantly reduced during the time of Impella support. During this time steroids were also applied to decrease the inflammatory response. However, importantly, when the Impella was removed, the inflammatory response significantly increased, despite continued steroid use (see Figure 3). This suggests that Impella support may provide clinically important additional antiinflammatory benefits beyond that observed with steroids alone. This pattern was seen for the levels of adhesion molecules ICAM-1 and VCAM-1, and also integrin receptors. Mass spectroscopic analysis of the biopsy samples revealed significant changes in protein composition, notably in the matrix proteins collagen and vimentin, which are important for integrin function. There was also a rapid improvement in titin function after unloading, which is essential for maintaining the elasticity of cardiomyocytes. Finally, energy consumption was assessed by measurement of glucose uptake and mitochondrial malate dehydrogenase. Again, a significant improvement was seen during the period of mechanical unloading.8

In conclusion, experience to date supports the hypothesis that prolonged unloading with an Impella device offers circulatory support with additional disease-modifying effects that are important for bridging fulminant myocarditis patients to recovery.

References

  1. Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis – natural history and treatment. Multicenter Giant Cell Myocarditis Study Group investigators, N Engl J Med 1997;336:1860–6.
    Crossref PubMed
  2. den Uil CA, Akin S, Jewbali LS, et al. Short-term mechanical circulatory support as a bridge to durable left ventricular assist device implantation in refractory cardiogenic shock: a systematic review and meta-analysis. Eur J Cardiothorac Surg 2017;52:14–25.
    Crossref PubMed
  3. Andrade JG, Al-Saloos H, Jeewa A, et al. Facilitated cardiac recovery in fulminant myocarditis: pediatric use of the Impella LP 5.0 pump. J Heart Lung Transplant 2010;29:96–7.
    Crossref PubMed
  4. Fox H, Farr M, Horstkotte D, et al. Fulminant myocarditis managed by extracorporeal life support (Impella® CP): a rare case. Case Rep Cardiol 2017;2017:9231959.
    Crossref PubMed
  5. Narain S, Paparcuri G, Fuhrman TM, et al. Novel combination of Impella and extra corporeal membrane oxygenation as a bridge to full recovery in fulminant myocarditis, Case Rep Crit Care 2012;2012:459296.
    Crossref PubMed
  6. Suradi H, Breall JA. Successful use of the Impella device in giant cell myocarditis as a bridge to permanent left ventricular mechanical support. Tex Heart Inst J 2011;38:437– 40.
    PubMed
  7. Perry P, David E, Atkins B, et al. Novel application of a percutaneous left ventricular assist device as a bridge to transplant in a paediatric patient with severe heart failure due to viral myocarditis. Interact Cardiovasc Thorac Surg 2017;24:474–6.
    Crossref PubMed
  8. Tschöpe C. J Cardiovasc Transl Res 2017. In press.